Categories: Health

Mesa Labs to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

 | Source: Mesa Laboratories, Inc.

LAKEWOOD, Colo., Dec. 18, 2025 (GLOBE NEWSWIRE) — Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced that Gary Owens, President and CEO, and John Sakys, CFO will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th, 2026. Management will participate in a Formal Presentation at 4:30 p.m. Pacific Time.

A live webcast of the presentation will be accessible here and on the Events & Presentations section of Mesa Lab’s Investor Relations website at https://investors.mesalabs.com/. An archived replay of the webcast will be available through the same link following the presentation.

About Mesa Laboratories, Inc.

Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.

For more information about Mesa, please visit its website at www.mesalabs.com.

Mesa Laboratories Contacts: 
Gary Owens; President and CEO,
John Sakys; CFO
1-303-987-8000
investors@mesalabs.com

GlobeNews Wire

Recent Posts

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogrens Disease at EULAR 2026

ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety RHO+…

2 hours ago

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Favorable safety and tolerability profile, with rapid onset of clinical activity and therapeutic effects observed…

2 hours ago

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Nipocalimab – the first neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus…

2 hours ago

GIGABYTE Unveils Next-Generation Gaming Peripherals with AORUS K10 INFINITY Keyboard and M10 INFINITY Mouse at COMPUTEX 2026

TAIPEI, June 3, 2026 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, unveiled its next-generation…

2 hours ago

Nationwide Celebrations mark Ruskin Bond’s 92nd Birthday

GURUGRAM, India, June 2, 2026 /PRNewswire/ -- On May 19, 2026, 92 bookstores across India…

8 hours ago

Canovation and CANPACK Formalize Collaboration to Accelerate CanReseal Toward Commercial Launch

The companies will align Canovation's resealable aluminum can-end technology with CANPACK's global manufacturing expertise to…

8 hours ago